Anti-Hypertensive Drugs - Gabon

Gabon

In Gabon, the revenue in the Anti-Hypertensive Drugs market is estimated to reach US$0.84m in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of -0.97%, leading to a market volume of US$0.80m by 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Gabon's anti-hypertensive drug market is witnessing a surge in demand due to the increasing prevalence of hypertension among the population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Gabon is showing interesting developments in recent years.

Customer preferences: Gabon's population is aging, and with age comes the increased likelihood of developing hypertension. This has led to a growing demand for anti-hypertensive drugs in the country. Additionally, the increasing awareness of the importance of managing hypertension has also contributed to the rise in demand for these drugs.

Trends in the market: The Anti-Hypertensive Drugs market in Gabon has been growing at a steady pace in recent years. The market has been driven by the increasing prevalence of hypertension in the country, as well as the growing awareness of the importance of managing hypertension. The market is expected to continue to grow in the coming years, driven by the aging population and the rising incidence of hypertension.

Local special circumstances: Gabon has a relatively small population, which means that the market for Anti-Hypertensive Drugs is limited. However, the country has a relatively high GDP per capita, which means that there is a relatively high level of disposable income among the population. This has allowed for the development of a niche market for high-end anti-hypertensive drugs.

Underlying macroeconomic factors: Gabon's economy is heavily dependent on the oil sector, which has been experiencing a decline in recent years. This has led to a slowdown in economic growth, which has had an impact on the healthcare sector. However, the government has been investing in the healthcare sector, which has helped to support the growth of the Anti-Hypertensive Drugs market. Additionally, the government has been working to improve access to healthcare services in the country, which has also contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.